Polaryx Taps CRO for Phase 2 Lysosomal Storage Disorder Trial

- The SOTERIA trial is a Phase 2, open-label, single-arm basket trial design, which allows for evaluating PLX-200 across four different lysosomal storage disorders (CLN2, CLN3, Krabbe disease, and Sandhoff disease) simultaneously, offering a more resource-efficient approach than traditional trial designs. For the CLN2 and CLN3 cohorts, the trial will incorporate analyses comparing the PLX-200 treated arm against natural history data as a control. - PLX-200 is a repurposed oral small molecule, specifically a formulation of gemfibrozil, an FDA-approved lipid-regulating agent. Its mechanism of action involves activating PPARα, which in turn boosts the production of Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis, aiming to address the core cellular deficit in these disorders. - The trial will enroll patients at sites in the United States, Europe, and potentially Asia, indicating the need for a robust data management infrastructure to handle multi-center and international data collection and ensure consistency. The management of data from such rare disease basket trials often leverages unified clinical data cloud platforms to aggregate, standardize, and analyze data from disparate sources. - The current standard of care for the targeted diseases is largely supportive, highlighting a significant unmet medical need. For Krabbe disease, hematopoietic stem cell transplantation (HSCT) can be beneficial but is most effective when performed before symptom onset and is not curative. For Sandhoff disease, treatment is focused on managing symptoms such as seizures and respiratory infections, with no cure currently available. - In the competitive landscape for CLN2 disease, BioMarin Pharmaceutical's Brineura (cerliponase alfa) is an approved enzyme replacement therapy, though it requires direct administration to the brain. Other companies, including REGENXBIO and Lexeo Therapeutics, are also developing gene therapies for various forms of Batten disease. - From a biomanufacturing perspective, the potential success of therapies like PLX-200 and others in the cell and gene therapy space for rare diseases relies on scalable and efficient manufacturing processes. The industry is increasingly looking at digital twins for bioprocess optimization and Laboratory Information Management Systems (LIMS) to manage the complex data and workflows inherent in cell and gene therapy development and GMP manufacturing. - Polaryx Therapeutics began trading on the Nasdaq Capital Market under the ticker "PLYX" on or around February 2, 2026, after a direct listing. As a clinical-stage company, it does not yet generate revenue, and its recent stock performance has been volatile since the IPO. - The Polaryx leadership team includes Alex Yang, J.D., LL.M., as CEO and Chairman, who has a background in fund formation and cross-border transactions, and Lisa Bollinger, M.D., as Chief Medical Officer, who has over 30 years of experience in drug development and regulatory affairs, including senior roles at Merck and Amgen.